Back to top
more

IDEXX Laboratories (IDXX)

(Real Time Quote from BATS)

$419.65 USD

419.65
299,328

-4.00 (-0.94%)

Updated Nov 15, 2024 01:48 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (65 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Here's Why You Should Buy Lantheus Holdings (LNTH) Right Now

by Zacks Equity Research

Lantheus Holdings (LNTH) banks on DEFINITY and TechneLite sales for growth. The company's focus on global expansion is also encouraging.

    Intuitive Surgical (ISRG) Well Poised on Procedural Business

    by Zacks Equity Research

    Intuitive Surgical's (ISRG) strong sales growth will continue to be aided by focus on da Vinci system and procedural growth from general surgery, oncology, urology and gynecology.

      LabCorp Grows on Solid Diagnostics, Currency Woes a Drag

      by Zacks Equity Research

      Although LabCorp's (LH) Covance drug development business puts up a dull performance, the market is upbeat about its Diagnostics business, which has recently displayed a solid show.

        Medtronic (MDT) Sees a Mixed Q1, New Products Bode Well

        by Zacks Equity Research

        Despite mixed results in Q1, Medtronic (MDT) displayed balanced growth with strength in three of its major business segments.

          PetMed Express Focuses on Advertising, Competition Rife

          by Zacks Equity Research

          PetMed Express (PETS) focuses on advertising to boost new order sales is striving to implement several strategies to revitalize its top line.

            Henry Schein's Merritt Buyout to Boost U.S. Veterinary Arm

            by Zacks Equity Research

            Henry Schein's (HSIC) acquisition of Merritt Veterinary supplies will brace its existing U.S. animal health business, particularly in the southeastern United States.

              LabCorp & Interpace Extend Deal, Boost Cancer Portfolio

              by Zacks Equity Research

              LabCorp's (LH) agreement to offer Interpace Diagnostics' molecular tests, ThyGenX and ThyraMIR gets renewed and extended for another two years.

                NxStage System One Gets FDA Nod for Solo Home Hemodialysis

                by Zacks Equity Research

                The latest regulatory go-ahead is likely to lend NxStage (NXTM) a competitive edge and expand its patient base with solid access to the clinical benefits associated with home hemodialysis.

                  Veeva (VEEV) to Gain Through Subscription Revenue Focus

                  by Zacks Equity Research

                  Veeva's (VEEV) strong sales growth will continue to be aided by focus on subscription revenue, better pricing and product innovation. However, higher costs remain a concern.

                    Hill-Rom (HRC) Stock Down With Dull Patient Support Systems

                    by Zacks Equity Research

                    Hill-Rom's (HRC) Patient Support Systems revenue decreases due to the adverse effect of the WatchChild and Architectural Products divestitures along with lower rental revenues.

                      LabCorp's $1.2 Billion Chiltern Buyout Gets FTC Approval

                      by Zacks Equity Research

                      The Federal Trade Commission (FTC) has granted LabCorp's (LH) request for an early closure of Chiltern's acquisition under HSR Act.

                        Express Scripts to Boost Oral Medication With Diabetes Study

                        by Zacks Equity Research

                        Express Scripts' (ESRX) new study will support oral diabetes medication and reduce related costs.

                          IDEXX Laboratories (IDXX), Great Growth Pick: Here's Why

                          by Zacks Equity Research

                          Banking on a number of favorable metrics, IDEXX Laboratories (IDXX) stands out as one of the most suitable growth stock.

                            Luminex (LMNX) Banks on FDA Approvals & Portfolio Strength

                            by Zacks Equity Research

                            Luminex (LMNX) has a broad range of products that are built on advanced technology. Also, it has collaborative agreements with several companies, which should help expand the use of its products.

                              Chemed (CHE) on Growth Track With VITAS & Roto-Rooter Arms

                              by Zacks Equity Research

                              The raised outlook for both Roto-Rooter unit and the bottom line indicate Chemed's (CHE) estimate of improved operating results in the upcoming quarters.

                                Illumina Teams Up With Telegraph Hill to Form Verogen

                                by Zacks Equity Research

                                Illumina (ILMC) and Telegraph Hill Partners plan to set up Verogen to accelerate adoption of NGS in the global forensic genomics market.

                                  Veeva Systems (VEEV) Beats Q2 Earnings, Revenue Estimates

                                  by Zacks Equity Research

                                  Veeva Systems (VEEV) witnessed stellar numbers in the second quarter owing to strong adoption of products like Veeva Network, Veeva Align, Veeva OpenData and Veeva CRM Approved Email.

                                    Align Technology-Patterson Dental Deal Expands iTero Reach

                                    by Zacks Equity Research

                                    Align Technology (ALGN) progresses with a slew of developments in the scanners and services segment.

                                      LabCorp to Add ChromaDex's Arm, Inorganic Expansion On Track

                                      by Zacks Equity Research

                                      LabCorp's (LH) decision to buy the analytical testing services arm of ChromaDex should fortify its Covance Food Solutions business.

                                        Stryker Recalls Sage Unit Products, Guidance Takes a Hit

                                        by Zacks Equity Research

                                        Added to the voluntary recall, Stryker (SYK) also placed a temporary hold on certain cloth-based products. Share price of Stryker declined massively following the news.

                                          Patterson Companies (PDCO) Beats on Q1 Earnings, Keeps View

                                          by Zacks Equity Research

                                          Patterson Companies' (PDCO) Animal Health business continues to contribute to the bottom line. Stable fiscal 2018 guidance instills investor confidence.

                                            Why IDEXX Laboratories (IDXX) Isn't Done Growing Earnings Yet

                                            by Zacks Equity Research

                                            IDEXX Laboratories (IDXX) is seeing solid earnings estimate revision and has a favorable Zacks rank, making it well positioned for future earnings growth.

                                              Civitas Solutions (CIVI) to Acquire Habilitative Services

                                              by Zacks Equity Research

                                              Civitas Solutions' (CIVI) proposed acquisition of Habilitative Services will aid the company in capturing the lucrative Minnesota market.

                                                Accuray (ARAY) Q4 Loss Wider Than Expected, Revenues Beat

                                                by Zacks Equity Research

                                                Accuray's (ARAY) new TomoTherapy product platform, also known as Radixact, continues to contribute to the top line. Solid Fiscal 2018 guidance instills investor confidence.

                                                  Medtronic's (MDT) CE Mark in Heart Lead Strengthens CVG Arm

                                                  by Zacks Equity Research

                                                  Medtronic's (MDT) CVG arm continues to be the highest revenue grossing segment. Thus, the company's CE Mark receipt for Attain Stability Quad MRI SureScan Active-Fixation heart lead buoys optimism.